Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight
Sponsor: Eli Lilly and Company
Summary
The main purpose of this study is to find out how significantly Eloralintide slows stomach emptying in participants who are overweight or obese. For each participant, the study will last approximately 21 weeks and will include 2 overnight stays in the clinical research unit (CRU) lasting between 4 and 8 days. There will be 13 other visits.
Official title: A Phase 1, Investigator- and Participant-Blinded, Placebo-Controlled, Randomized, Multiple-Dose Study to Evaluate the Gastric Emptying Delay, Pharmacokinetics, Safety, and Tolerability of Eloralintide in Participants With Obesity or Overweight
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
56
Start Date
2026-07-31
Completion Date
2026-12
Last Updated
2026-08-20
Healthy Volunteers
Yes
Conditions
Interventions
Eloralintide
Administered SC
Placebo
Administered SC
Acetaminophen
Administered Oral Solution
Locations (2)
ICON Early Phase Services
San Antonio, Texas, United States
Lilly Centre for Clinical Pharmacology
Singapore, Singapore